Insulin Aspart vs Plecanatide
Head-to-head comparison of Insulin Aspart (Insulin aspart (B28-Asp human insulin analog)) and Plecanatide (Plecanatide) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Insulin Aspart | Plecanatide |
|---|---|---|
| Category | Diabetes & Metabolic | Gastrointestinal |
| Full Name | Insulin aspart (B28-Asp human insulin analog) | Plecanatide |
| Molecular Weight | 5825.8 Da | Approx. 1620 Da |
| Half-Life | About 1-3 hours | Local intestinal action; systemic half-life not clinically meaningful |
| Amino Acids | 51 | 16 |
| Typical Dose | 0.05-0.2 U/kg per meal | 3 mg once daily |
| Route | Subcutaneous | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 11000 | 350 |
| Research Status | Approved | Clinical |
Insulin Aspart Benefits
- ✓Fast post-meal glucose lowering
- ✓Predictable onset
- ✓Flexible mealtime administration
- ✓Compatible with pump therapy
Plecanatide Benefits
- ✓improves-stool-frequency
- ✓supports-fluid-secretion
- ✓may-reduce-constipation
- ✓local-gut-action
Insulin Aspart Dosing
Inject SC immediately before meals|Titrate using glucose monitoring and carbohydrate intake|Can be used in insulin pumps or basal-bolus regimens
Plecanatide Dosing
3 mg PO daily|take with or without food|avoid when dehydrated
Insulin Aspart Side Effects
- ⚠Hypoglycemia
- ⚠Injection-site reactions
- ⚠Weight gain
Plecanatide Side Effects
- ⚠diarrhea
- ⚠abdominal-discomfort
- ⚠nausea
Research Overview
Insulin Aspart
Research consistently shows faster onset and earlier peak action than regular human insulin. It is commonly studied for meal-time glycemic control and pump-based insulin delivery.
Plecanatide
Clinical trials show plecanatide improves constipation outcomes with a generally favorable tolerability profile. Like linaclotide, it acts locally in the intestinal lumen via GC-C signaling rather than systemic hormone effects.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.